Key Points
-
Polymorphisms of the gene encoding A20 confer susceptibility to multiple autoimmune and inflammatory diseases, including systemic lupus erythematosus, rheumatoid arthritis, psoriasis, coeliac disease, inflammatory bowel disease, type 2 diabetes and atherosclerosis.
-
A20 is a tumour suppressor for human lymphomas, as biallelic somatic mutations that inactivate A20 occur at a high frequency in human B cell lymphomas.
-
A20-deficient mice die perinatally owing to multiorgan inflammation. Lineage-specific deletions of the gene encoding A20 have shown that A20 performs a variety of cell type-specific functions that prevent autoimmunity and autoinflammatory diseases.
-
A20 regulates multiple ubiquitin-dependent cellular activation and survival signals downstream of tumour necrosis factor receptors, Toll-like receptors, the interleukin-1 receptor, NOD-like receptors, CD40 and antigen receptors.
-
A20 is a multifunctional protein that binds to K63-linked and linear polyubiquitin chains and exhibits both de-ubiquitylation and E3 ubiquitin ligase activities. How these activities are coordinated, and how they are utilized in distinct signalling complexes, is currently unclear.
-
A20 cooperates with other ubiquitin-binding and ubiquitin-modifying proteins to form larger ubiquitin-editing complexes that may provide higher degrees of specificity and regulation of ubiquitin-dependent signalling.
-
The extensive associations of A20 and its associated proteins with human diseases suggest that modification of the expression or functions of A20 may provide potent therapeutic opportunities.
Abstract
A20 (also known as TNFAIP3) is a potent anti-inflammatory signalling molecule that restricts multiple intracellular signalling cascades. Recent studies in three general areas have converged to highlight the clinical and biological importance of A20. First, human genetic studies have strongly linked polymorphisms and mutations in the gene encoding A20 to inflammatory, autoimmune and malignant diseases. Second, studies in gene-targeted mice have revealed that A20 regulates multiple immune cell functions and prevents experimental diseases that closely mimic human conditions. Third, biochemical studies have unveiled complex mechanisms by which A20 regulates ubiquitin-dependent nuclear factor-κB and cell-survival signals. Taken together, these studies are revealing the importance of A20-mediated regulation of ubiquitin-dependent signalling in human disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
£169.00 per year
only £14.08 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Baltimore, D. NF-κB is 25. Nature Immunol. 12, 683–685 (2011).
Rui, L., Schmitz, R., Ceribelli, M. & Staudt, L. M. Malignant pirates of the immune system. Nature Immunol. 12, 933–940 (2011).
Greten, F. R. et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118, 285–296 (2004).
Pickart, C. M. & Eddins, M. J. Ubiquitin: structures, functions, mechanisms. Biochim. Biophys. Acta 1695, 55–72 (2004).
Chen, Z. J. Ubiquitination in signaling to and activation of IKK. Immunol. Rev. 246, 95–106 (2012).
Komander, D. & Rape, M. The ubiquitin code. Ann. Rev. Biochem. 81, 203–229 (2012).
Cooper, J. T. et al. A20 blocks endothelial cell activation through a NF-κB-dependent mechanism. J. Biol. Chem. 271, 18068–18073 (1996).
Hutti, J. E. et al. IκB kinase β phosphorylates the K63 deubiquitinase A20 to cause feedback inhibition of the NF-κB pathway. Mol. Cell. Biol. 27, 7451–7461 (2007).
Coornaert, B. et al. T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-κB inhibitor A20. Nature Immunol. 9, 263–271 (2008).
Shrikhande, G. V. et al. O-glycosylation regulates ubiquitination and degradation of the anti-inflammatory protein A20 to accelerate atherosclerosis in diabetic ApoE-null mice. PLoS ONE 5, e14240 (2010).
Opipari, A. W. Jr, Hu, H. M., Yabkowitz, R. & Dixit, V. M. The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. J. Biol. Chem. 267, 12424–12427 (1992).
Heyninck, K. et al. The zinc finger protein A20 inhibits TNF-induced NF-κB-dependent gene expression by interfering with an RIP- or TRAF2-mediated transactivation signal and directly binds to a novel NF-κB-inhibiting protein ABIN. J. Cell Biol. 145, 1471–1482 (1999).
Heyninck, K. & Beyaert, R. The cytokine-inducible zinc finger protein A20 inhibits IL-1-induced NF-κB activation at the level of TRAF6. FEBS Lett. 442, 147–150 (1999).
Lee, E. G. et al. Failure to regulate TNF-induced NF-κB and cell death responses in A20-deficient mice. Science 289, 2350–2354 (2000). This study unveiled the profound anti-inflammatory functions of A20 in mice, and the requirement for A20 in restricting TNF-induced NF-κB signals.
Boone, D. L. et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nature Immunol. 5, 1052–1060 (2004).
Hitotsumatsu, O. et al. The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals. Immunity 28, 381–390 (2008).
Turer, E. E. et al. Homeostatic MyD88-dependent signals cause lethal inflammation in the absence of A20. J. Exp. Med. 205, 451–464 (2008). References 15 and 17 revealed a crucial role for A20 in restricting basal MYD88-dependent TLR signals that drive a major component of the spontaneous inflammation seen in A20-deficient mice.
Tavares, R. M. et al. The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity. Immunity 33, 181–191 (2010). This study showed that A20 limits the induction of BCL-X expression and promotes the FAS-mediated death of activated B cells, providing a potential molecular underpinning for the tumour-suppressive function of A20 in human B cell lymphomas (see references 50–54).
Chu, Y. et al. B cells lacking the tumor suppressor TNFAIP3/A20 display impaired differentiation and hyperactivation and cause inflammation and autoimmunity in aged mice. Blood 117, 2227–2236 (2011). References 18 and 19 showed that B cell-specific expression of A20 restricts autoantibody production and germinal centre B cell numbers, providing potential pathophysiological mechanisms underlying human genetic studies linking A20 polymorphisms with SLE (see references 26–31).
Lin, S. C. et al. Molecular basis for the unique deubiquitinating activity of the NF-κB inhibitor A20. J. Mol. Biol. 376, 526–540 (2008).
Komander, D. & Barford, D. Structure of the A20 OTU domain and mechanistic insights into deubiquitination. Biochem. J. 409, 77–85 (2008).
Wertz, I. E. et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature 430, 694–699 (2004). This study demonstrated that two distinct motifs in the A20 protein exhibit de-ubiquitylase and ubiquitin ligase activity towards RIP1, providing an unusual and novel biochemical mechanism for the restriction of NF-κB signalling.
Bosanac, I. et al. Ubiquitin binding to A20 ZnF4 is required for modulation of NF-κB signaling. Mol. Cell 40, 548–557 (2010). This study demonstrated that the ZF4 motif of A20 directly binds to ubiquitin and ubiquitylated E2 enzymes.
Skaug, B. et al. Direct, noncatalytic mechanism of IKK inhibition by A20. Mol. Cell 44, 559–571 (2011). This study demonstrated that the seventh zinc finger of A20, ZF7, binds to ubiquitin and directly inhibits TAK1-mediated activation of IKKγ activity. This function occurs independently of the C103 DUB motif of A20.
Vereecke, L., Beyaert, R. & van Loo, G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol. 30, 383–391 (2009).
Graham, R. R. et al. Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nature Genet. 40, 1059–1061 (2008).
Musone, S. L. et al. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nature Genet. 40, 1062–1064 (2008).
Han, J. W. et al. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nature Genet. 41, 1234–1237 (2009).
Cai, L. Q. et al. A single-nucleotide polymorphism of the TNFAIP3 gene is associated with systemic lupus erythematosus in Chinese Han population. Mol. Biol. Rep. 37, 389–394 (2010).
Shimane, K. et al. The association of a nonsynonymous single-nucleotide polymorphism in TNFAIP3 with systemic lupus erythematosus and rheumatoid arthritis in the Japanese population. Arthritis Rheum. 62, 574–579 (2010).
Adrianto, I. et al. Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nature Genet. 43, 253–258 (2011).
Musone, S. L. et al. Sequencing of TNFAIP3 and association of variants with multiple autoimmune diseases. Genes Immun. 12, 176–182 (2011).
Plenge, R. M. et al. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nature Genet. 39, 1477–1482 (2007).
Thomson, W. et al. Rheumatoid arthritis association at 6q23. Nature Genet. 39, 1431–1433 (2007).
Elsby, L. M. et al. Functional evaluation of TNFAIP3 (A20) in rheumatoid arthritis. Clin. Exp. Rheumatol. 28, 708–714 (2010).
Hughes, L. B. et al. Most common single-nucleotide polymorphisms associated with rheumatoid arthritis in persons of European ancestry confer risk of rheumatoid arthritis in African Americans. Arthritis Rheum. 62, 3547–3553 (2010).
Eyre, S. et al. Overlapping genetic susceptibility variants between three autoimmune disorders: rheumatoid arthritis, type 1 diabetes and coeliac disease. Arthritis Res. Ther. 12, R175 (2010).
Nair, R. P. et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways. Nature Genet. 41, 199–204 (2009).
Strange, A. et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nature Genet. 42, 985–990 (2010).
Fung, E. Y. et al. Analysis of 17 autoimmune disease-associated variants in type 1 diabetes identifies 6q23/TNFAIP3 as a susceptibility locus. Genes Immun. 10, 188–191 (2009).
Trynka, G. et al. Coeliac disease-associated risk variants in TNFAIP3 and REL implicate altered NF-κB signalling. Gut 58, 1078–1083 (2009).
Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661–678 (2007).
Hammer, G. E., et al. Dendritic cell expression of A20 preserves immune homeostasis and prevents colitis and spondyloarthritis. Nature Immunol. 12, 1184–1193 (2011). This study (together with reference 62) demonstrated that A20 expression in DCs is crucial for preserving immune homeostasis. In this study, mice with A20-deficient DCs developed seronegative arthritis, colitis and spondyloarthritis, resembling a stereotypical human syndrome associated with inflammatory bowel disease.
Boonyasrisawat, W. et al. Tag polymorphisms at the A20 (TNFAIP3) locus are associated with lower gene expression and increased risk of coronary artery disease in type 2 diabetes. Diabetes 56, 499–505 (2007).
Dieudé, P. et al. Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian population. Ann. Rheum. Dis. 69, 1958–1964 (2010).
Koumakis, E. et al. Candidate gene study in systemic sclerosis identifies a rare and functional variant of TNFAIP3 locus as a risk factor for individual polyautoimmunity. Arthritis Rheum. 64, 2746–2752 (2012).
Koczan, D. et al. Molecular discrimination of responders and nonresponders to anti-TNFα therapy in rheumatoid arthritis by etanercept. Arthritis Res. Ther. 10, R50 (2008).
Arsenescu, R. et al. Signature biomarkers in Crohn's disease: toward a molecular classification. Mucosal Immunol. 1, 399–411 (2008).
Tejasvi, T. et al. TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J. Invest. Dermatol. 132, 593–600 (2011).
Kato, M. et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 459, 712–716 (2009).
Compagno, M. et al. Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma. Nature 459, 717–721 (2009). References 50 and 51 showed that the reintroduction of A20 into A20-deficient lymphomas suppressed tumour cell growth and apoptosis, suggesting that A20 is a tumour suppressor.
Novak, U. et al. The NF-κB negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood 113, 4918–4921 (2009).
Honma, K. et al. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood 114, 2467–2475 (2009).
Braun, F. C. et al. Tumor suppressor TNFAIP3 (A20) is frequently deleted in Sézary syndrome. Leukemia 25, 1494–1501 (2011). References 50–54 demonstrated that biallelic somatic mutations of the gene encoding A20 are frequently present in human B and T cell lymphomas.
Malynn, B. A. & Ma, A. A20 takes on tumors: tumor suppression by an ubiquitin-editing enzyme. J. Exp. Med. 206, 977–980 (2009).
Hymowitz, S. G. & Wertz, I. E. A20: from ubiquitin editing to tumour suppression. Nature Rev. Cancer 10, 332–341 (2010).
Chanudet, E. et al. A20 is targeted by promoter methylation, deletion and inactivating mutation in MALT lymphoma. Leukemia 24, 483–487 (2010).
Thome, M. Multifunctional roles for MALT1 in T-cell activation. Nature Rev. Immunol. 8, 495–500 (2008).
Malinverni, C. et al. Cleavage by MALT1 induces cytosolic release of A20. Biochem. Biophys. Res. Commun. 400, 543–547 (2010).
Hövelmeyer, N. et al. A20 deficiency in B cells enhances B-cell proliferation and results in the development of autoantibodies. Eur. J. Immunol. 41, 595–601 (2011).
Vucic, D., Dixit, V. M. & Wertz, I. E. Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. Nature Rev. Mol. Cell Biol. 12, 439–452 (2011).
Kool, M. et al. The ubiquitin-editing protein A20 prevents dendritic cell activation, recognition of apoptotic cells, and systemic autoimmunity. Immunity 35, 82–96 (2011). Along with reference 43, this study demonstrated the importance of A20 expression to DC functions. Interestingly, these mice developed systemic autoimmunity, a distinct immunological phenotype from that of the mice described in reference 43.
Song, X. T. et al. A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nature Med. 14, 258–265 (2008).
Breckpot, K. et al. Attenuated expression of A20 markedly increases the efficacy of double-stranded RNA-activated dendritic cells as an anti-cancer vaccine. J. Immunol. 182, 860–870 (2009).
Hong, B. et al. Mucosal and systemic anti-HIV immunity controlled by A20 in mouse dendritic cells. J. Clin. Invest. 121, 739–751 (2011).
Honda, K. & Littman, D. R. The microbiome in infectious disease and inflammation. Annu. Rev. Immunol. 30, 759–795 (2012).
Matmati, M. et al. A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nature Genet. 43, 908–912 (2011). This study showed that mice with A20-deficient myeloid cells spontaneously develop severe polyarthritis, providing potential pathophysiological mechanisms that may underlie the link between TNFAIP3 polymorphisms and rheumatoid arthritis.
Maelfait, J. et al. A20 (Tnfaip3) deficiency in myeloid cells protects against influenza A virus infection. PLoS Pathog. 8, e1002570 (2012).
Vereecke, L. et al. Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. J. Exp. Med. 207, 1513–1523 (2010). This study showed that mice with a specific ablation of A20 in IECs show increased susceptibility to experimental colitis, providing potential pathophysiological mechanisms that may underlie the link between TNFAIP3 polymorphisms and inflammatory bowel disease (see references 42 and 43).
Rakoff-Nahoum, S. & Medzhitov, R. Role of the innate immune system and host–commensal mutualism. Curr. Top. Microbiol. Immunol. 308, 1–18 (2006).
Wang, J., Ouyang, Y., Guner, Y., Ford, H. R. & Grishin, A. V. Ubiquitin-editing enzyme A20 promotes tolerance to lipopolysaccharide in enterocytes. J. Immunol. 183, 1384–1392 (2009).
Kolodziej, L. E. et al. TNFAIP3 maintains intestinal barrier function and supports epithelial cell tight junctions. PLoS ONE 6, e26352 (2011).
Lippens, S. et al. Keratinocyte-specific ablation of the NF-κB regulatory protein A20 (TNFAIP3) reveals a role in the control of epidermal homeostasis. Cell Death Differ. 8, 1845–1853 (2011).
Sun, L. D. et al. Association analyses identify six new psoriasis susceptibility loci in the Chinese population. Nature Genet. 42, 1005–1009 (2010).
Harhaj, E. W. & Dixit, V. M. Deubiquitinases in the regulation of NF-κB signaling. Cell Res. 21, 22–39 (2011).
Bach, F. H. et al. Accommodation of vascularized xenografts: expression of “protective genes” by donor endothelial cells in a host Th2 cytokine environment. Nature Med. 3, 196–204 (1997).
Ferran, C. Protective genes in the vessel wall: modulators of graft survival and function. Transplantation 82 (Suppl. 1), S36–S40 (2006).
Zhu, C. et al. Development of anti-atherosclerotic tissue-engineered blood vessel by A20-regulated endothelial progenitor cells seeding decellularized vascular matrix. Biomaterials 29, 2628–2636 (2008).
Idel, S., Dansky, H. M. & Breslow, J. L. A20, a regulator of NFκB, maps to an atherosclerosis locus and differs between parental sensitive C57BL/6J and resistant FVB/N strains. Proc. Natl Acad. Sci. USA 100, 14235–14240 (2003).
Wolfrum, S., Teupser, D., Tan, M., Chen, K. Y. & Breslow, J. L. The protective effect of A20 on atherosclerosis in apolipoprotein E-deficient mice is associated with reduced expression of NF-κB target genes. Proc. Natl Acad. Sci. USA 104, 18601–18606 (2007).
Shembade, N., Ma, A. & Harhaj, E. W. Inhibition of NF-κB signaling by A20 through disruption of ubiquitin enzyme complexes. Science 327, 1135–1139 (2010). This study described a role for A20 in disrupting the functions of E2 and E3 enzymes, thereby limiting ubiquitin ligase activity.
Evans, P. C. et al. Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity. Biochem. J. 378, 727–734 (2004).
Deng, L. et al. Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103, 351–361 (2000).
Ea, C. K., Sun, L., Inoue, J. & Chen, Z. J. TIFA activates IκB kinase (IKK) by promoting oligomerization and ubiquitination of TRAF6. Proc. Natl Acad. Sci. USA 101, 15318–15323 (2004).
Gao, L. et al. ABIN1 protein cooperates with TAX1BP1 and A20 proteins to inhibit antiviral signaling. J. Biol. Chem. 286, 36592–36602 (2011).
Düwel, M. et al. A20 negatively regulates T cell receptor signaling to NF-κB by cleaving Malt1 ubiquitin chains. J. Immunol. 182, 7718–7728 (2009).
Nakada, S. et al. Non-canonical inhibition of DNA damage-dependent ubiquitination by OTUB1. Nature 466, 941–946 (2010).
Jin, Z. et al. Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell 137, 721–735 (2009).
Song, H. Y., Rothe, M. & Goeddel, D. V. The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-κB activation. Proc. Natl Acad. Sci. USA 93, 6721–6725 (1996).
Verhelst, K. et al. A20 inhibits LUBAC-mediated NF-κB activation by binding linear polyubiquitin chains via its zinc finger 7. EMBO J. 28 Aug 2012 (doi:10.1038/emboj.2012.240).
Tokunaga, F. et al. Specific recognition of linear polyubiquitin by A20 zinc finger 7 is involved in NF-κB regulation. EMBO J. 28 Aug 2012 (doi:101038/emboj.2012.241).
Wang, T. et al. Evidence for bidentate substrate binding as the basis for the K48 linkage specificity of otubain 1. J. Mol. Biol. 386, 1011–1023 (2009).
Sims, J. J. & Cohen, R. E. Linkage-specific avidity defines the lysine 63-linked polyubiquitin-binding preference of Rap80. Mol. Cell 33, 775–783 (2009).
Heyninck, K., Van Huffel, S., Kreike, M. & Beyaert, R. Yeast two-hybrid screening for proteins interacting with the anti-apoptotic protein A20. Methods Mol. Biol. 282, 223–241 (2004).
Mauro, C. et al. ABIN-1 binds to NEMO/IKKγ and co-operates with A20 in inhibiting NF-κB. J. Biol. Chem. 281, 18482–18488 (2006).
Shembade, N. et al. The E3 ligase Itch negatively regulates inflammatory signaling pathways by controlling the function of the ubiquitin-editing enzyme A20. Nature Immunol. 9, 254–262 (2008).
Li, L., Soetandyo, N., Wang, Q. & Ye, Y. The zinc finger protein A20 targets TRAF2 to the lysosomes for degradation. Biochim. Biophys. Acta 1793, 346–353 (2009).
Shembade, N., Parvatiyar, K., Harhaj, N. S. & Harhaj, E. W. The ubiquitin-editing enzyme A20 requires RNF11 to downregulate NF-κB signalling. EMBO J. 28, 513–522 (2009).
Oshima, S. et al. ABIN-1 is a ubiquitin sensor that restricts cell death and sustains embryonic development. Nature 457, 906–909 (2009). This study demonstrated a crucial function for ABIN1, a protein that may bind to and support A20, in restricting TNF signals and preserving embryonic survival.
Nanda, S. K. et al. Polyubiquitin binding to ABIN1 is required to prevent autoimmunity. J. Exp. Med. 208, 1215–1228 (2011). This study showed that ABIN1 restricts TLR as well as TNF signals and prevents autoimmunity.
Zhou, J. et al. A20-binding inhibitor of NF-κB (ABIN1) controls Toll-like receptor-mediated CCAAT/enhancer-binding protein β activation and protects from inflammatory disease. Proc. Natl Acad. Sci. USA 108, e998–e1006 (2011).
Gateva, V. et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nature Genet. 41, 1228–1233 (2009).
Bowes, J. et al. Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis. Ann. Rheum. Dis. 70, 1641–1644 (2011).
Dong, G. et al. A20, ABIN-1/2, and CARD11 mutations and their prognostic value in gastrointestinal diffuse large B-cell lymphoma. Clin. Cancer Res. 17, 1440–1451 (2011).
Yan, Q. et al. BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas. Haematologica 97, 595–598 (2012).
Wagner, S. et al. Ubiquitin binding mediates the NF-κB inhibitory potential of ABIN proteins. Oncogene 27, 3739–3745 (2008).
Lin, W. J. et al. Crucial role for TNF receptor-associated factor 2 (TRAF2) in regulating NFκB2 signaling that contributes to autoimmunity. Proc. Natl Acad. Sci. USA 108, 18354–18359 (2011).
Lomaga, M. A. et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 13, 1015–1024 (1999).
Perry, W. L. et al. The itchy locus encodes a novel ubiquitin protein ligase that is disrupted in a18H mice. Nature Genet. 18, 143–146 (1998).
Iha, H. et al. Inflammatory cardiac valvulitis in TAX1BP1-deficient mice through selective NF-κB activation. EMBO J. 27, 629–641 (2008).
Shembade, N., Harhaj, N. S., Liebl, D. J. & Harhaj, E. W. Essential role for TAX1BP1 in the termination of TNF-α-, IL-1- and LPS-mediated NF-κB and JNK signaling. EMBO J. 26, 3910–3922 (2007).
Parvatiyar, K., Barber, G. N. & Harhaj, E. W. TAX1BP1 and A20 inhibit antiviral signaling by targeting TBK1–IKKi kinases. J. Biol. Chem. 285, 14999–15009 (2010).
Kim, S. W. et al. MicroRNAs miR-125a and miR-125b constitutively activate the NF-κB pathway by targeting the tumor necrosis factor α-induced protein 3 (TNFAIP3, A20). Proc. Natl Acad. Sci. USA 109, 7865–7870 (2012).
Graff, J. W., Dickson, A. M., Clay, G., McCaffrey, A. P. & Wilson, M. E. Identifying functional microRNAs in macrophages with polarized phenotypes. J. Biol. Chem. 287, 21816–21825 (2012).
Gantier, M. P. et al. A miR-19 regulon that controls NF-κB signaling. Nucleic Acids Res. 40, 8048–8058 (2012).
Iwai, K. Diverse ubiquitin signaling in NF-κB activation. Trends Cell Biol. 22, 355–364 (2012).
Walczak, H., Iwai, K. & Dikic, I. Generation and physiological roles of linear ubiquitin chains. BMC Biol. 10, 23 (2012).
Acknowledgements
Work from the authors' laboratory was supported by the US National Institutes of Health.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Glossary
- Ubiquitylation
-
The covalent attachment of single ubiquitin molecules or ubiquitin chains to proteins to regulate their interactions with proteasomal components and other proteins. Protein ubiquitylation occurs in three enzymatic steps that require a ubiquitin-activating enzyme (E1), a ubiquitin-conjugating enzyme (E2) and a ubiquitin ligase (E3), respectively. The ligase catalyses the formation of an isopeptide bond between the carboxyl terminus of ubiquitin and an amino group belonging to a lysine residue of the target protein.
- Single-nucleotide polymorphisms
-
(SNPs). Variations in DNA sequence in which one of the four nucleotides is substituted for another (for example, C for A). SNPs are the most frequent type of polymorphism in the genome.
- Apoptosis
-
A common form of cell death. Many physiological and developmental stimuli cause apoptosis, and this mechanism is frequently used to delete unwanted, superfluous or potentially harmful cells, such as those undergoing transformation.
- Activation-induced cytidine deaminase
-
(AID). An enzyme that is required for two crucial events in the germinal centre: somatic hypermutation and class-switch recombination.
- Dextran sulphate sodium (DSS)-induced colitis
-
A commonly used experimental model of colitis induced in mice by ingestion of the sulphated polysaccharide DSS. This model causes acute colonic epithelial damage and inflammation via unknown mechanisms.
- Tight junctions
-
A belt-like region of adhesion between adjacent epithelial or endothelial cells that regulates paracellular flux. Tight-junction proteins include the integral membrane proteins occludin and claudin, in association with cytoplasmic zonula occludens proteins.
- Ectodysplasin A receptor
-
(EDAR). A member of the TNFR family that can activate NF-κB-, JNK- and caspase-independent cell signalling pathways. EDAR pathways are important for the development of ectodermal structures, such as hair follicles, sweat glands and teeth.
- Cellular inhibitor of apoptosis
-
A family of proteins (comprising cIAP1, cIAP2, XIAP and NAIP) that contain a BIR domain and that can act as E3 ubiquitin ligases and as inhibitors of caspases.
- MicroRNAs
-
Endogenous single-stranded RNA molecules of approximately 21–23 nucleotides in length that regulate the expression of other genes by binding to mRNAs and inducing RNA degradation.
Rights and permissions
About this article
Cite this article
Ma, A., Malynn, B. A20: linking a complex regulator of ubiquitylation to immunity and human disease. Nat Rev Immunol 12, 774–785 (2012). https://doi.org/10.1038/nri3313
Published:
Issue date:
DOI: https://doi.org/10.1038/nri3313
This article is cited by
-
Propofol Ameliorates Spinal Cord Injury Process by Mediating miR-672-3p/TNIP2 Axis
Biochemical Genetics (2024)
-
The Complexity of Being A20: From Biological Functions to Genetic Associations
Journal of Clinical Immunology (2024)
-
Increased Intestinal Permeability: An Avenue for the Development of Autoimmune Disease?
Exposure and Health (2024)
-
Association between polymorphisms of anti-inflammatory gene alleles and periodontitis risk in a Chinese Han population
Clinical Oral Investigations (2023)
-
Study of clinical factors, focus score, lymphocyte type and NF-κB pathway in Sjögren’s syndrome
Odontology (2023)